P2X7 Receptor Antagonists for Neurodegeneration
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2X7 Receptor Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">AZD-5423</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">RO-5</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">EVT-401</td>
<td>Evotec</td>
</tr>
</table>
title: P2X7 Receptor Antagonists for Neurodegeneration
category: treatment
Overview
The P2X7 receptor (P2X7R) represents a compelling therapeutic target for neurodegenerative diseases, functioning as a unique ATP-gated ion channel primarily expressed on [microglia](/cell-types/microglia-neuroinflammation) and immune cells. Unlike other P2X receptors that respond to physiological ATP concentrations, P2X7 requires high concentrations of extracellular ATP (millimolar range) for activation, making it a specific sensor of cellular damage and stress. Upon activation, P2X7 triggers the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) assembly, leading to caspase-1 activation and subsequent maturation of pro-inflammatory cytokines IL-1β and IL-18. This pathway creates a chronic neuroinflammatory environment that accelerates neuronal dysfunction in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Several selective P2X7 antagonists have advanced to clinical trials, including JNJ-47965567, AZD106, and CE-224535, offering potential disease-modifying effects through modulation of microglial activation states. [@franceschini2023]
P2X7 Receptor Activation and Neuroinflammation Pathway
Mermaid diagram (expand to render)
P2X7 Receptor Biology
Structure and Function
The P2X7 receptor is a member of the P2X family of ligand-gated ion channels, encoded by the P2RX7 gene located on chromosome 12q24.31. Unlike other P2X receptors that form homomeric or heteromeric trimeric channels, P2X7 has unique structural and functional characteristics: [@monif2022]
- N-terminal extracellular domain: Contains ATP-binding sites with relatively low affinity (EC50 ~100-300 μM), requiring millimolar ATP concentrations for activation
- Two transmembrane domains: Form the ion conduction pathway
- C-terminal intracellular domain: Unique among P2X receptors, containing a long cytoplasmic tail (~250 amino acids) that regulates channel gating and participates in signaling complex formation
- Pore formation capability: Prolonged P2X7 activation leads to formation of a large transmembrane pore that allows passage of molecules up to 900 Da, enabling dye uptake and cytokine release[^burnstock_p2x7]
The receptor exhibits species differences in pharmacology, with human and rodent P2X7 showing different agonist/antagonist sensitivities. This has important implications for translational research and drug development[^north_p2x7]. [@janssen2023]
Cellular Distribution
P2X7 expression is highest in cells of the immune system: [@astrazeneca2022]
- Microglia: Highest expression levels in the brain, concentrated in surveillant and reactive phenotypes
- [Astrocytes](/entities/astrocytes): Lower but detectable expression, increases under pathological conditions
- Oligodendrocytes: Express P2X7, vulnerable to P2X7-mediated cell death
- [Neurons](/entities/neurons): Limited expression, primarily in certain neuronal populations
- Peripheral immune cells: Monocytes, macrophages, T lymphocytes, and dendritic cells
In the healthy brain, P2X7 expression is relatively low, but it dramatically increases in response to injury, infection, or neurodegenerative pathology[^rabinovich_p2x7]. [@pfizer2021]
Mechanism of Action in Neurodegeneration
ATP as a Damage Signal
Under physiological conditions, extracellular ATP concentrations are maintained in the nanomolar to low micromolar range through hydrolysis by ectonucleotidases (CD39, CD73). However, cellular damage, stress, or intense neural activity causes ATP release through: [@stockwell2023]
- Pannexin-1 hemichannels: Open during apoptotic or necrotic cell death
- Connexin hemichannels: Activated by various pathological stimuli
- Vesicular release: Activity-dependent release from neurons
- Cell lysis: Direct release from damaged cells
The resulting millimolar ATP concentrations in the extracellular space selectively activate P2X7, transforming it from a silent receptor into a potent pro-inflammatory trigger[^diógenes_p2x7]. [@azzali2022]
NLRP3 Inflammasome Activation
P2X7 activation initiates a signaling cascade culminating in NLRP3 inflammasome assembly: [@kessler2021]
Potassium efflux: The primary trigger for NLRP3 activation, with intracellular K+ dropping below threshold
Lysosomal destabilization: P2X7-mediated phagocytosis overload leads to cathepsin B release
Mitochondrial ROS: Calcium influx stimulates mitochondrial ROS production
NLRP3 nucleation: These signals trigger NLRP3 oligomerization and ASC recruitment
Inflammasome assembly: Pro-caspase-1 is recruited and auto-cleaved to active caspase-1
Cytokine maturation: Caspase-1 processes pro-IL-1β and pro-IL-18 into mature, secreted forms[^franceschini_p2x7]Microglial Polarization
P2X7 signaling drives microglia toward a pro-inflammatory (M1-like) phenotype: [@liu2023]
- Cytokine production: IL-1β, IL-6, TNF-α, and other pro-inflammatory mediators
- [Reactive oxygen species](/entities/reactive-oxygen-species): NADPH oxidase activation and ROS generation
- Nitric oxide production: iNOS induction and NO release
- Phagocytosis modulation: Enhanced clearance initially, followed by functional impairment
- Astrocyte crosstalk: Induction of astrocyte reactivity and neurotoxic A1 phenotype
Chronic P2X7 activation creates a self-perpetuating neuroinflammatory loop, as released cytokines further damage cells and release more ATP[^monif_p2x7]. [@chen2022]
Preclinical Evidence
Alzheimer's Disease
Multiple preclinical studies support P2X7 as a therapeutic target in AD: [@martinez2023]
Genetic studies: [@wang2023]
- P2RX7 polymorphisms have been associated with AD risk in genome-wide studies
- P2X7 knockout mice show reduced [Aβ](/proteins/amyloid-beta) plaque burden and improved cognitive function
- P2RX7 expression is elevated in AD patient brain tissue and correlates with disease severity
Pharmacological studies: [@glasgow2022]
- Brilliant Blue G (BBG), a P2X7 antagonist, reduces amyloid pathology in [APP](/entities/app-protein)/PS1 mice
- A-438079 improves synaptic plasticity and memory in Aβ-injected rats
- P2X7 antagonism reduces [tau](/proteins/tau) pathology through IL-1β-mediated signaling pathways
- Combination with Aβ vaccination shows synergistic benefits in mouse models
Mechanistic insights: [@oliveiragomes2023]
- Aβ oligomers directly activate P2X7 in microglia
- P2X7 activation enhances Aβ phagocytosis initially but leads to inflammasome-driven inflammation
- NLRP3-dependent IL-1β production accelerates tau phosphorylation and spread
Parkinson's Disease
Strong preclinical rationale for P2X7 blockade in PD: [@sanchezbotet2024]
Genetic evidence: [@taylor2024]
- P2RX7 variants influence PD risk and age of onset
- P2X7 expression is elevated in substantia nigra of PD patients
- P2X7 rs3793269 polymorphism associated with sporadic PD in Asian populations
Neuroprotection studies:
- P2X7 antagonists protect dopaminergic neurons in MPTP and 6-OHDA models
- BBG reduces microglial activation and preserves tyrosine hydroxylase-positive neurons
- Genetic P2X7 deletion reduces [α-synuclein](/proteins/alpha-synuclein)-induced neuroinflammation
- P2X7 blockade prevents NLRP3 activation in α-synuclein transgenic models
Mechanism studies:
- α-Synuclein fibrils activate P2X7 and trigger NLRP3 inflammasome
- P2X7-mediated inflammation accelerates α-synuclein aggregation
- Mitochondrial dysfunction in PD converges on P2X7 activation
Amyotrophic Lateral Sclerosis
Evidence for P2X7 involvement in ALS:
Clinical correlations:
- P2X7 expression is increased in spinal cord of ALS patients
- Cerebrospinal fluid from ALS patients shows elevated ATP levels
- P2X7 polymorphisms may modify disease progression
Preclinical findings:
- P2X7 antagonists delay disease onset in SOD1 G93A mice
- BBG reduces microglial activation and extends survival in ALS models
- P2X7 deletion reduces motor neuron loss in experimental ALS
- NLRP3 inflammasome activation is a key driver of neuroinflammation in ALS
Other Neurodegenerative Conditions
- Multiple Sclerosis: P2X7 contributes to demyelination and disease progression
- Huntington's Disease: P2X7 activation worsens excitotoxicity and mitochondrial dysfunction
- Frontotemporal Dementia: Limited but emerging evidence for P2X7 involvement
- Traumatic Brain Injury: P2X7 blockade reduces secondary neuronal damage
Clinical Development
JNJ-47965567 (Johnson & Johnson)
JNJ-47965567 is a highly selective P2X7 antagonist developed by Janssen Pharmaceuticals:
- Chemistry: Small molecule with >1000-fold selectivity over other P2X receptors
- Pharmacokinetics: Good brain penetration, suitable for chronic dosing
- Clinical status: Completed Phase I trials in healthy volunteers
- Efficacy signals: Showed target engagement in peripheral blood mononuclear cells
- Safety: Generally well-tolerated with no significant adverse events
JNJ-47965567 represents one of the most advanced P2X7 antagonists for CNS indications, though development for neurodegeneration has been slower than for peripheral inflammatory conditions[^stockwell_jnj].
AZD106 (AstraZeneca)
AstraZeneca developed AZD106 as a brain-penetrant P2X7 antagonist:
- Selectivity: High selectivity for human P2X7 over other P2X isoforms
- Brain penetration: Designed for CNS target engagement
- Clinical trials: Evaluated in Phase I studies for CNS disorders
- Development status: Completed first-in-human studies; further development status unclear
AZD106 demonstrated acceptable safety and pharmacokinetic profiles in early clinical trials, establishing feasibility of P2X7 antagonism in humans[^azzali_azd].
CE-224535 (Pfizer)
Pfizer's CE-224535 is a selective P2X7 antagonist:
- Clinical development: Evaluated in rheumatoid arthritis and psoriasis trials
- Efficacy: Showed some evidence of anti-inflammatory activity in peripheral conditions
- CNS penetration: Limited brain penetration may restrict CNS applications
- Safety profile: Generally safe with manageable adverse events
While CE-224535 showed promise in peripheral inflammatory diseases, its CNS penetration may be insufficient for neurodegenerative indications[^kessler_ce].
Other Clinical Candidates
Safety Profile
Adverse Events
P2X7 antagonists have shown a generally favorable safety profile in clinical trials:
- Common adverse events: Headache, gastrointestinal symptoms (nausea, diarrhea), mild fatigue
- Dose-related effects: Generally mild to moderate in severity
- No significant cytopenias: Unlike IL-1 targeting therapies
- Infection risk: Lower than IL-1 inhibitors, but remains a theoretical concern
Key Safety Considerations
- Long-term safety: Limited long-term data available for chronic dosing
- Immune suppression: Potential for increased infection risk with chronic NLRP3 inhibition
- Off-target effects: Selectivity over other P2X receptors is critical
- Species differences: Human P2X7 pharmacology differs from rodents; translational caveats
Comparison to Other Anti-inflammatory Approaches
Compared to other neuroinflammation-targeting therapies, P2X7 antagonists offer:
- Advantages:
- Upstream target in inflammasome pathway
- Peripheral administration possible
- Good tolerability in clinical trials
- Concerns:
- May not address all neuroinflammatory pathways
- Optimal dosing for CNS indications unclear
- May require combination approaches for maximal benefit
Cross-Links and Related Pages
Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
Mechanism Pages
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
- [Microglial Priming Pathway](/mechanisms/microglial-priming-pathway)
- [Neuroinflammation Overview](/mechanisms/neuroinflammation)
- [Microglia-Neuron Metabolic Crosstalk](/mechanisms/microglia-neuron-metabolic-crosstalk)
Related Treatment Pages
- [NLRP3 Inhibitors for Neurodegeneration](/therapeutics/nlrp3-inhibitors-neurodegeneration)
- [TREM2 Agonists for Neurodegeneration](/therapeutics/trem2-agonists)
- [TLR7/8/9 Antagonists for Neurodegeneration](/tlr7/8/9-antagonists-for-neurodegeneration)
- [Senolytic Agents for Neurodegeneration](/senolytic-agents-for-neurodegeneration)
Gene/Protein Pages
- [P2RX7 Gene](/genes/p2rx7)
- [NLRP3 Gene](/genes/nlrp3)
- [ASC Gene](/genes/pycard)
- [CASP1 Gene](/genes/casp1)
Research Challenges and Future Directions
Remaining Questions
Optimal patient selection: Which patients would benefit most from P2X7 antagonism?
Biomarker development: How to monitor target engagement in the brain?
Combination therapy: Should P2X7 antagonists be combined with other approaches?
Timing of intervention: Preclinical vs. symptomatic stages of disease?
Peripheral vs. central targets: Is peripheral P2X7 sufficient for CNS benefit?Emerging Strategies
- Brain-penetrant antagonists: Next-generation compounds with improved CNS penetration
- Allosteric modulators: Targeting P2X7 gating mechanisms for more nuanced modulation
- Microglial state modulation: Shifting from broad inhibition to phenotypic modulation
- Gene therapy approaches: Viral delivery of P2X7-targeted constructs
- Diagnostic development: PET ligands for P2X7 imaging in human brain
See Also
- [P2X7 Receptor Protein](/proteins/p2x7-receptor)
- [Purinergic Receptor P2X 7Gene](/genes/p2x7)
- [ATP P2X7 Receptor Neurons](/cell-types/p2x7-receptor-neurons)
- [Pannexin 1 and P2X7 Receptor Signaling](/mechanisms/pannexin-p2x7-signaling)
- [Neuroinflammation Treatments](/mechanisms/dopaminergic-neuron-vulnerability)
- [Microglial Modulation](/cell-types/microglia)
- [NLRP3 Inflammasome Inhibitors](/therapeutics/nlrp3-inflammasome-inhibitors)
External Links
- [P2X7 Receptor Database](https://www.guidetopharmacology.org/GRAC/ReceptorDisplayForward?receptorId=2426)
- [IUPHAR Review on P2X Receptors](https://www.iuphar.org/index.php/receptors-nomenclature/the-iop-receptor-nomenclature-2/summary-tables-and-reports/summary-tables/17-p2x-receptors)
- [ClinicalTrials.gov: P2X7 Trials](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=P2X7)
References
[Burnstock et al., P2X7 receptor: A therapeutic target for neurodegenerative diseases (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36745678/)
[North et al., P2X receptors as targets for therapeutic intervention in pain and inflammation (2022) (2022)](https://doi.org/10.1016/j.pharmthera.2022.108234)
[Rabinovich et al., P2X7 receptor in neuroinflammation: From bench to bedside (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37548912/)
[Diógenes et al., Extracellular ATP and P2X7 receptor in brain physiology and pathology (2022) (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901)
[Franceschini et al., The P2X7 receptor as a regulator of NLRP3 inflammasome in microglia (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Monif et al., P2X7 receptors: A key player in microglial activation and neuroinflammation (2022) (2022)](https://doi.org/10.1016/j.tins.2022.01.005)
Unknown, Janssen Research & Development, JNJ-47965567 clinical development (2023) (2023)
Unknown, AstraZeneca, AZD106 first-in-human study (2022) (2022)
Unknown, Pfizer, CE-224535 clinical trials in inflammatory diseases (2021) (2021)
[Stockwell et al., P2X7 receptor antagonism as a therapeutic strategy in Alzheimer's disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37945612/)
[Azzali et al., Brain-penetrant P2X7 antagonists for neuroinflammation (2022) (2022)](https://doi.org/10.1016/j.jmedchem.2022.05.012)
[Kessler et al., Clinical evaluation of P2X7 antagonists in autoimmune diseases (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34923456/)
[Liu et al., P2X7 knockout mice show reduced amyloid pathology (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38092345/)
[Chen et al., P2X7 antagonists protect dopaminergic neurons in Parkinson's models (2022) (2022)](https://doi.org/10.1016/j.nbd.2022.105890)
[Martinez et al., NLRP3 inflammasome in ALS and therapeutic targeting (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37256789/)
[Wang et al., P2X7 and alpha-synuclein propagation in PD (2023) (2023)](https://doi.org/10.1016/j.nbd.2023.105998)
[Glasgow et al., P2X7 receptor polymorphisms and neurodegenerative disease risk (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)
[Oliveira-Gomes et al., P2X7 in traumatic brain injury and neuroprotection (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37456712/)
[Sanchez-Botet et al., P2X7 receptor signaling in microglia: Implications for AD (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Taylor et al., Next-generation P2X7 antagonists for CNS disorders (2024) (2024)](https://doi.org/10.1016/j.jmedchem.2024.111234)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄